These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 7729635)

  • 1. Delivery and fate of oral mesalamine microgranules within the human small intestine.
    Layer PH; Goebell H; Keller J; Dignass A; Klotz U
    Gastroenterology; 1995 May; 108(5):1427-33. PubMed ID: 7729635
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oroileal transit of slow release 5-aminosalicylic acid.
    Goebell H; Klotz U; Nehlsen B; Layer P
    Gut; 1993 May; 34(5):669-75. PubMed ID: 8504969
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Significance of galenic preparations for luminal release of 5-aminosalicylic acid in human small intestinal lumen].
    Keller J; Goebell H; Klotz U; Layer P
    Med Klin (Munich); 1998 May; 93(5):294-9. PubMed ID: 9630813
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 5-Aminosalicylic acid containing drugs. Delivery, fate, and possible clinical implications in man.
    Christensen LA
    Dan Med Bull; 2000 Feb; 47(1):20-41. PubMed ID: 10709142
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bioavailability of single and multiple doses of a new oral formulation of 5-ASA in patients with inflammatory bowel disease and healthy volunteers.
    Gionchetti P; Campieri M; Belluzzi A; Boschi S; Brignola C; Miglioli M; Barbara L
    Aliment Pharmacol Ther; 1994 Oct; 8(5):535-40. PubMed ID: 7865646
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bioavailability of controlled release mesalazine (5-ASA) preparations.
    Rasmussen SN
    J Gastroenterol; 1995 Nov; 30 Suppl 8():112-4. PubMed ID: 8563869
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical pharmacokinetics of slow release mesalazine.
    De Vos M
    Clin Pharmacokinet; 2000 Aug; 39(2):85-97. PubMed ID: 10976656
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Localization of drug release sites from an oral sustained-release formulation of 5-ASA (Pentasa) in the gastrointestinal tract using gamma scintigraphy.
    Hardy JG; Harvey WJ; Sparrow RA; Marshall GB; Steed KP; Macarios M; Wilding IR
    J Clin Pharmacol; 1993 Aug; 33(8):712-8. PubMed ID: 8408731
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Release of 5-ASA from Pentasa in patients with Crohn's disease of the small intestine.
    Larouche J; Morais J; Picard M; Lambert C; Spénard J; Landriault H; Kennedy G; Poitras P
    Aliment Pharmacol Ther; 1995 Jun; 9(3):315-20. PubMed ID: 7654894
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of an enteric-coated delayed-release 5-aminosalicylic acid tablet in patients with inflammatory bowel disease.
    Hardy JG; Healey JN; Reynolds JR
    Aliment Pharmacol Ther; 1987 Aug; 1(4):273-80. PubMed ID: 2979672
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Topical and systemic availability of 5-aminosalicylate: comparisons of three controlled release preparations in man.
    Christensen LA; Fallingborg J; Abildgaard K; Jacobsen BA; Sanchez G; Hansen SH; Bondesen S; Hvidberg EF; Rasmussen SN
    Aliment Pharmacol Ther; 1990 Oct; 4(5):523-33. PubMed ID: 2129640
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative pharmacokinetics of equimolar doses of 5-aminosalicylate administered as oral mesalamine (Asacol) and balsalazide: a randomized, single-dose, crossover study in healthy volunteers.
    Sandborn WJ; Hanauer SB; Buch A
    Aliment Pharmacol Ther; 2004 May; 19(10):1089-98. PubMed ID: 15142198
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The release profile of a controlled release preparation of 5-aminosalicylic acid (Rowasa I) in humans.
    McLeod RS; Cohen Z; Vari BJ; Blair JE; Greenberg GR
    Dis Colon Rectum; 1990 Jan; 33(1):21-5. PubMed ID: 2295273
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabolism and urinary excretion of 5-amino salicylic acid in healthy volunteers when given intravenously or released for absorption at different sites in the gastrointestinal tract.
    Myers B; Evans DN; Rhodes J; Evans BK; Hughes BR; Lee MG; Richens A; Richards D
    Gut; 1987 Feb; 28(2):196-200. PubMed ID: 3557190
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Distribution and anti-inflammatory effect of mesalazine on carrageenan-induced colitis in the rabbit.
    Kitano A; Matsumoto T; Oshitani N; Nakagawa M; Yasuda K; Watanabe Y; Tomobuchi M; Obayashi M; Tabata A; Fukushima R; Okabe H; Nakamura S; Obata A; Okawa K; Kobayashi K
    Clin Exp Pharmacol Physiol; 1996 Apr; 23(4):305-9. PubMed ID: 8717066
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gastrointestinal transit and release of mesalazine tablets in patients with inflammatory bowel disease.
    Healey JN
    Scand J Gastroenterol Suppl; 1990; 172():47-51. PubMed ID: 2353171
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic studies of benzalazine.
    Herzog R; Leuschner J
    Arzneimittelforschung; 1994 Dec; 44(12):1381-3. PubMed ID: 7848362
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gastrointestinal spread of oral prolonged-release mesalazine microgranules (Pentasa) dosed as either tablets or sachet.
    Wilding IR; Kenyon CJ; Hooper G
    Aliment Pharmacol Ther; 2000 Feb; 14(2):163-9. PubMed ID: 10651656
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 5-Aminosalicylic acid concentration in mucosal interstitium of cat small and large intestine.
    Grisham MB; Granger DN
    Dig Dis Sci; 1989 Apr; 34(4):573-8. PubMed ID: 2702889
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bioavailability of single and multiple doses of enteric-coated mesalamine and sulphasalazine.
    Corey AE; Rose GM; Conklin JD
    J Int Med Res; 1990; 18(6):441-53. PubMed ID: 1981363
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.